UY34775A - Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple - Google Patents

Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple

Info

Publication number
UY34775A
UY34775A UY0001034775A UY34775A UY34775A UY 34775 A UY34775 A UY 34775A UY 0001034775 A UY0001034775 A UY 0001034775A UY 34775 A UY34775 A UY 34775A UY 34775 A UY34775 A UY 34775A
Authority
UY
Uruguay
Prior art keywords
laquinimod
treatment
multiple sclerosis
high dose
dose
Prior art date
Application number
UY0001034775A
Other languages
English (en)
Spanish (es)
Inventor
Dan Bar-Zohar
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34775(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34775A publication Critical patent/UY34775A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
UY0001034775A 2012-05-02 2013-04-30 Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple UY34775A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02

Publications (1)

Publication Number Publication Date
UY34775A true UY34775A (es) 2013-11-29

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034775A UY34775A (es) 2012-05-02 2013-04-30 Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple

Country Status (21)

Country Link
US (3) US20130303569A1 (cg-RX-API-DMAC7.html)
EP (1) EP2844255A4 (cg-RX-API-DMAC7.html)
JP (2) JP2015515985A (cg-RX-API-DMAC7.html)
KR (1) KR20150013658A (cg-RX-API-DMAC7.html)
CN (2) CN105832733A (cg-RX-API-DMAC7.html)
AR (1) AR090885A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013256352A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014027010A2 (cg-RX-API-DMAC7.html)
CA (1) CA2870684A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014002935A1 (cg-RX-API-DMAC7.html)
EA (1) EA201492010A1 (cg-RX-API-DMAC7.html)
HK (1) HK1206246A1 (cg-RX-API-DMAC7.html)
IL (1) IL235337A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014013039A (cg-RX-API-DMAC7.html)
PE (1) PE20150161A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502447A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201406594UA (cg-RX-API-DMAC7.html)
TW (2) TW201347762A (cg-RX-API-DMAC7.html)
UY (1) UY34775A (cg-RX-API-DMAC7.html)
WO (1) WO2013166166A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408820B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
TW201345527A (zh) 2012-02-03 2013-11-16 Teva Pharma 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
AU2013329348A1 (en) * 2012-10-12 2015-05-28 Teva Pharmaceutical Industries Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
EA201591699A1 (ru) 2013-03-14 2016-02-29 Тева Фармасьютикал Индастриз Лтд. Кристаллы лаквинимода натрия и улучшенный способ их производства
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
US20150306088A1 (en) * 2014-04-29 2015-10-29 Teva Pharmaceutical Industries, Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
WO2020016850A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
CN106344576A (zh) * 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症

Also Published As

Publication number Publication date
US20160000775A1 (en) 2016-01-07
PH12014502447A1 (en) 2015-01-12
PE20150161A1 (es) 2015-02-22
AR090885A1 (es) 2014-12-10
CN104284663A (zh) 2015-01-14
CN105832733A (zh) 2016-08-10
US20130303569A1 (en) 2013-11-14
WO2013166166A1 (en) 2013-11-07
TW201804997A (zh) 2018-02-16
CL2014002935A1 (es) 2015-03-06
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
TW201347762A (zh) 2013-12-01
MX2014013039A (es) 2015-02-04
KR20150013658A (ko) 2015-02-05
JP2015515985A (ja) 2015-06-04
CA2870684A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
EA201492010A1 (ru) 2015-06-30
EP2844255A4 (en) 2015-10-14
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
EP2844255A1 (en) 2015-03-11
ZA201408820B (en) 2016-06-29
HK1206246A1 (en) 2016-01-08
AU2013256352A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX378273B (es) Compuestos activos hacia bromodominios.
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
JOP20140104B1 (ar) مركبات ثنائى اريل اميد كمثبطات كيناز
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
CL2016001895A1 (es) Compuestos
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
CL2015002897A1 (es) Inhibidores de bace1
MX374944B (es) Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria.
UA114417C2 (uk) Інгібітори iap
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526